These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 9373804)

  • 1. Asymptomatic hyperammonemia in children treated with valproic acid.
    Altunbaşak S; Baytok V; Tasouji M; Hergüner O; Burgut R; Kayrin L
    J Child Neurol; 1997 Oct; 12(7):461-3. PubMed ID: 9373804
    [No Abstract]   [Full Text] [Related]  

  • 2. The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.
    Hamed SA; Abdella MM
    Epilepsy Res; 2009 Sep; 86(1):32-41. PubMed ID: 19446440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs.
    Verrotti A; Greco R; Morgese G; Chiarelli F
    Int J Clin Lab Res; 1999; 29(1):36-40. PubMed ID: 10356662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valproate-associated hyperammonemia and DL-carnitine supplement.
    Komatsu M; Kodama S; Yokoyama S; Konishi H; Tanaka K; Momota K; Wada H; Matsuo T
    Kobe J Med Sci; 1987 Jun; 33(3):81-7. PubMed ID: 2959815
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of carnitine supplementation in valproate-induced hyperammonaemia.
    Böhles H; Sewell AC; Wenzel D
    Acta Paediatr; 1996 Apr; 85(4):446-9. PubMed ID: 8740302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive side effects of valproic acid-induced hyperammonemia in children with epilepsy.
    Nicolai J; Aldenkamp AP; Huizenga JR; Teune LK; Brouwer OF
    J Clin Psychopharmacol; 2007 Apr; 27(2):221-4. PubMed ID: 17414255
    [No Abstract]   [Full Text] [Related]  

  • 7. Serum carnitine, beta-hydroxybutyrate and ammonia levels during valproic acid therapy.
    Toksoy HB; Tanzer FN; Atalay A
    Turk J Pediatr; 1995; 37(1):25-9. PubMed ID: 7732605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carnitine deficiency and hyperammonemia associated with valproic acid therapy.
    Ohtani Y; Endo F; Matsuda I
    J Pediatr; 1982 Nov; 101(5):782-5. PubMed ID: 6813444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of glutamine synthetase gene polymorphisms on the development of hyperammonemia during valproic acid-based therapy.
    Inoue K; Takahashi T; Yamamoto Y; Suzuki E; Takahashi Y; Imai K; Inoue Y; Hirai K; Tsuji D; Itoh K
    Seizure; 2015 Dec; 33():76-80. PubMed ID: 26599579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs.
    Thom H; Carter PE; Cole GF; Stevenson KL
    Dev Med Child Neurol; 1991 Sep; 33(9):795-802. PubMed ID: 1936631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Valproate-induced hyperammonemia in asymptomatic children.
    Wyllie E; Wyllie R; Rothner AD; Erenberg G; Cruse RP
    Cleve Clin Q; 1983; 50(3):275-7. PubMed ID: 6418412
    [No Abstract]   [Full Text] [Related]  

  • 12. [Incidence of pathologic ammonia concentrations in the plasma in children with seizure disorders treated with Convulsofin/Convulex and other anticonvulsants in comparison with children with brain damage and healthy children].
    Wiedemann G; Haupt M; Rommel A; Rommel KF; Biesenbach R; Schmidt W
    Kinderarztl Prax; 1990 Jan; 58(1):21-7. PubMed ID: 2110274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diet- and valproate-induced transient hyperammonemia: effect of L-carnitine.
    Gidal BE; Inglese CM; Meyer JF; Pitterle ME; Antonopolous J; Rust RS
    Pediatr Neurol; 1997 May; 16(4):301-5. PubMed ID: 9258962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intractable epilepsy.
    Shuper A; Gutman A; Mimouni M
    Lancet; 1999 Apr; 353(9160):1238. PubMed ID: 10217085
    [No Abstract]   [Full Text] [Related]  

  • 15. 4217C>A polymorphism in carbamoyl-phosphate synthase 1 gene may not associate with hyperammonemia development during valproic acid-based therapy.
    Inoue K; Suzuki E; Takahashi T; Yamamoto Y; Yazawa R; Takahashi Y; Imai K; Miyakawa K; Inoue Y; Tsuji D; Hayashi H; Itoh K
    Epilepsy Res; 2014 Aug; 108(6):1046-51. PubMed ID: 24888247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The problems of valproate therapy in severely handicapped children--valproate induced hyperammonemia and hypocarnitinemia].
    Matsui K; Iwamoto H; Ohtsuki N; Kobayashi T; Miyake S; Yamada M
    No To Hattatsu; 1991 Jan; 23(1):32-8. PubMed ID: 1825272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperammonemia following intravenous valproate loading.
    DeWolfe JL; Knowlton RC; Beasley MT; Cofield S; Faught E; Limdi NA
    Epilepsy Res; 2009 Jul; 85(1):65-71. PubMed ID: 19299111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-carnitine supplementation in childhood epilepsy: current perspectives.
    De Vivo DC; Bohan TP; Coulter DL; Dreifuss FE; Greenwood RS; Nordli DR; Shields WD; Stafstrom CE; Tein I
    Epilepsia; 1998 Nov; 39(11):1216-25. PubMed ID: 9821988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Carglumic acid for treatment of valproic acid-induced hyperammonaemia in a paediatric patient].
    Gramage Caro T; Vélez-Díaz-Pallarés M; Serna Pérez J; Bermejo Vicedo T
    Farm Hosp; 2012; 36(5):437-8. PubMed ID: 22858088
    [No Abstract]   [Full Text] [Related]  

  • 20. [A case report of valproate encephalopathy].
    Miyamoto T; Miyamoto M; Hirata K; Katayama S
    Rinsho Shinkeigaku; 1999 Oct; 39(10):1075-7. PubMed ID: 10655774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.